ViVerita Therapeutics Enters into Collaboration with Boehringer Ingelheim to Discovery of Novel Cancer Targets
Thursday, May 08, 2025
ViVerita Therapeutics has announced a new research collaboration with Boehringer Ingelheim.
The partnership aims to speed up the discovery and validation of new therapeutic targets in cancer treatment.
As part of the agreement, ViVerita will use its advanced in vivo CRISPR-based discovery platform to study a selection of potential cancer targets provided by Boehringer Ingelheim. These targets will be tested under conditions that closely mimic the real environment inside the body, offering a more accurate understanding of their potential effectiveness.
Cancer remains a leading global health challenge, accounting for one in every six deaths worldwide. Despite ongoing efforts, treatment options for many forms of cancer remain limited. One of the main reasons is that most current drug discovery efforts focus on a narrow group of well-known targets. This collaboration seeks to widen the scope by exploring new, less-understood targets that may lead to more effective treatments.
Traditional methods of identifying cancer targets often rely on cell lines grown in lab settings. While useful, these methods do not always reflect the complex conditions found in the body, particularly within the tumour microenvironment. As a result, many promising targets identified in vitro fail to deliver results when tested in vivo.
ViVerita’s platform offers a solution by combining large-scale genetic screening with disease models that more closely represent real-life cancer conditions. This approach allows for the discovery and testing of new cancer-driving targets that are difficult to identify using conventional tools.
The partnership supports Boehringer Ingelheim’s ongoing strategy to uncover clinically relevant cancer mechanisms and develop innovative treatments for patients with high unmet medical needs. The collaboration is expected to enhance the development of first-in-class therapies by focusing on previously overlooked biological pathways in cancer.
Through this alliance, both companies aim to make meaningful progress in cancer research and offer new hope to patients around the world.
Source: prnewswire.com
